Karyopharm Therapeutics to Present New Data on Selective Inhibitor of Nuclear Export (SINE), KPT-330, at 2013 EHA CongressNatick, Mass. – May 28, 2013 – Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announced that data for its lead compound KPT-330 against advanced chronic myeloid leukemia (CML) will be presented in the CML Biology oral abstract session at the 18th Congress of the European Hematology Association (EHA) to be held June 13th – 15th, 2013 in Stockholm, Sweden.
“We are pleased that these data on our novel XPO1/CRM1 inhibitor KPT-330 in accelerated and blast crisis phase CML will be presented in an oral session at the EHA annual congress,” commented Karyopharm Chief Scientific Officer and founder Sharon Shacham, Ph.D. “These data, in an important hematologic malignancy, complement our upcoming presentation of KPT-330 in patients with advanced solid tumors at ASCO.”
The presentation will highlight preclinical data from blast-crisis CML models and report on pilot clinical results in this indication. Phase 1 studies of KPT-330 are ongoing in patients with relapsed or refractory hematologic malignancies (NCT01607892) and solid tumors (NCT01607905), whose disease has progressed on currently available treatments.
Dr. Chris Walker from the Ohio State University will present “Preclinical and Clinical Efficacy of KPT-330-Mediated XPO1 Inhibition in Ph+ Leukemias” on Saturday, June 15, 2013, at 4:30-4:45 PM in Hall C6/7 (Abstract S602).
KPT-330 is one of the company’s family of novel selective inhibitors of nuclear export (SINE) compounds that induces cell death selectively in cancer cells through forced nuclear retention and activation of tumor suppressor proteins by blocking Exportin 1 (XPO1/CRM1). It is the first oral, small molecule XPO1 antagonist ever to be tested in humans.
Karyopharm Therapeutics Inc. is a clinical-stage biopharmaceutical company leading the new field of nuclear transport modulators. Karyopharm’s selective inhibitors of nuclear export (SINE) function by trapping multiple tumor suppressor proteins in the nucleus, resulting in anti-cancer activity across multiple tumor types. Karyopharm’s lead SINE KPT-330 is in two Phase 1 clinical studies for advanced solid tumor and hematologic malignancies. The related SINE KPT-335 is being tested in a pivotal study as an oral treatment for dogs with Non-Hodgkin’s Lymphoma, one of the most common canine cancers. The Company is also testing SINEs in autoimmune, viral and dermatologic disorders. Karyopharm Therapeutics was founded by Drs. Sharon Shacham and Michael Kauffman and is located in Natick, Massachusetts.
THIS PRESS RELEASE CONTAINS ARCHIVAL INFORMATION WHICH SHOULD NOT BE CONSIDERED CURRENT AND MAY NO LONGER BE ACCURATE